Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$103.46 - $126.29 $36,521 - $44,580
-353 Reduced 27.39%
936 $100,000
Q4 2022

Feb 14, 2023

SELL
$36.06 - $117.21 $104,393 - $339,322
-2,895 Reduced 69.19%
1,289 $141,000
Q3 2022

Nov 14, 2022

BUY
$28.17 - $59.01 $901 - $1,888
32 Added 0.77%
4,184 $247,000
Q2 2022

Aug 12, 2022

SELL
$22.39 - $38.94 $16,501 - $28,698
-737 Reduced 15.07%
4,152 $117,000
Q1 2022

May 16, 2022

SELL
$30.13 - $50.0 $8,496 - $14,100
-282 Reduced 5.45%
4,889 $185,000
Q4 2021

Feb 14, 2022

SELL
$22.28 - $39.54 $86,268 - $153,098
-3,872 Reduced 42.82%
5,171 $204,000
Q3 2021

Nov 15, 2021

SELL
$20.89 - $26.96 $9,943 - $12,832
-476 Reduced 5.0%
9,043 $214,000
Q2 2021

Aug 10, 2021

BUY
$16.8 - $29.65 $159,919 - $282,238
9,519 New
9,519 $234,000

Others Institutions Holding RXDX

About Prometheus Biosciences, Inc.


  • Ticker RXDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,904,100
  • Description
  • Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...
More about RXDX
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.